Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC

Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC

Introduction: Gene rearrangements are frequent oncologic drivers in NSCLC, and many are suitable for treatment with Food and Drug Administration–approved or experimental targeted therapies. We evaluated the accuracy, specimen acceptance profile, and limits of detection of a rapid fusion assay (Idyll...

Full description

Bibliographic Details
Main Authors: Alessia Buglioni, MD, Patricia L. Caffes, BS, MBA, Mark G. Hessler, BS, CG(ASCP), Aaron S. Mansfield, MD, Ying-Chun Lo, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:JTO Clinical and Research Reports
Subjects:
Gene fusions
Rapid testing
Non–small cell lung cancer
Targeted therapy
Idylla
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001588

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001588

Similar Items